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     BSTRACT
In the second part of this review article , the diagnostic aspects of thyroid scintigraphy are 
discussed, with major emphasis on hyperthyroidism, followed by an overview of radioiodine 
treatment. 
SAMENVATTING
In het tweede deel van dit overzichtsartikel worden de diagnostische aspecten van schildklierscinti-
grafie besproken, met de nadruk op hyperthyreoïdie, gevolgd door een overzicht van de behandeling 
met radioactief jodium.
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SCINTIGRAPHY
Scintigraphy stands out as an imaging modality 
by providing not only anatomical but also functional 
information. One of the most common applications 
of scintigraphy is the evaluation of thyroid function, 
i.e. to assess the degree of thyroid gland radionuclide 
uptake, to confirm hyperthyroidism in doubtful cases 
or for use in patients with non-thyroidal illness. 
The radionuclide mostly used in thyroid scintig-
raphy is 99mtechnetium (99mTc) or its chemical form 
pertechnetate (99mTcO4-). 99mTc is obtained from a 
99molybdenium (99Mo) generator and has a physi-
cal half-life of six hours. It decays by emitting elec-
tromagnetic γ-radiation of 140 keV, which will be 
detected by the NaI crystal within the gamma camera 
(Kintzer and Peterson, 1994; Kowalsky, 2006).
Another radionuclide that can be used in thyroid 
imaging is 123iodine (123I), which decays by the emis-
sion of electromagnetic γ-rays (159 keV). In contrary 
to pertechnetate, 123I will be organified in the thyroid 
gland and incorporated in the normal iodine metabolic 
pathway. It has a longer physical half-life of approxi-
mately 13 hours. The ideal imaging time for 123I is 
strongly delayed at eight hours after injection com-
pared to technetium that allows scanning from twenty 
minutes on. Another major drawback of 123I is the 
high cost in comparison to pertechnetate (Kintzer and 
Peterson, 1994; Broome, 2006; Daniel and Brawner, 
2006; Kowalsky, 2006). Although theoretically pos-
sible, another radioisotope of iodine, 131I, is gener-
ally not used for imaging given its longer half-life, 
high cost and inferior image quality, which results 
from the high energy γ-photons (364 keV). Further, 
131I also emits β-particles that, given their destructive 
nature, are usable for therapeutic purposes but do not 
contribute to diagnostic scans (Kintzer and Peterson, 
1994; Shiel and Mooney, 2007). This will be further 
addressed in the chapter about radioiodine therapy. 
Diagnostic scintigraphy in this article will always refer 
to the use of pertechnetate.
Protocol
Thyroid scintigraphy is based on the ability of the 
thyroid follicular cell’s iodide pump to trap iodide 
as well as pertechnetate (99mTcO4-). The pertechnetate 
ion has a similar size and charge as iodide and will be 
trapped, but is not used in thyroglobulin organification 
and hormone production, nor will it be stored in the 
colloid fluid like iodide is stored. It will be excreted 
into the bloodstream and removed from the body, 
mainly via the kidneys (Kintzer and Peterson, 1994; 
Broome, 2006; Daniel and Brawner, 2006).
It is important to remember that the iodide pumps 
are also present at the level of the salivary glands, the 
gastric mucosa, the choroid plexus, the ciliary body of 
the eye, the placenta and lactating mammary glands 
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(Daniel and Brawner, 2006; Capen, 2007). More spe-
cifically, uptake at the level of the head is seen in the 
nasal cavity, the region of the nasopharynx and soft 
palate, and at the level of the zygomatic, molar, parotid 
and mandibular salivary glands. The major hot focus 
seen on a typical feline pertechnetate scan represents 
the combination of the zygomatic and molar salivary 
glands. Radionuclide uptake in the area of the media-
stinum may represent the esophagus containing sa-
liva, or blood pool activity in one of the large vessels. 
Therefore, uptake in these areas should not be mis-
taken for an abnormality (Daniel and Brawner, 2006). 
The radionuclide is injected intravenously prior 
Figure 1. Hyperthyroid cat positioned for a thyroid scan. 
The cat is placed on the scan bed in ventral recumbency. 
The head of the gamma camera underneath the table 
records the activity at the level of the thyroid glands. 
The head of the gamma camera on top is not active in 
this case.
Figure 2. Thyroid scan of a normal cat. The same image is presented in A and B. B. shows the different regions of 
interest (ROI) typically drawn on a thyroid scan: thyroid lobe (1), salivary gland (2), background ROI in the axillary 
region (3), background ROIs in the cervical area (4). (L: left).
to the scan to allow the substance to be trapped by 
the thyroid gland and cleared from the soft tissues. 
Cats will receive an activity of 18.5 to 148 MBq of 
pertechnetate, with an average of 74 MBq. Scans can 
be acquired from twenty minutes after injection on-
wards, with a peak uptake in feline thyroid glands seen 
at 45 - 60 minutes (Kintzer and Peterson, 1994; Daniel 
and Brawner, 2006; Daniel and Neelis, 2014). The cat 
is then positioned in ventral recumbency above the 
camera (Figure 1). The scan is performed using a low 
energy - high resolution (LEHR) collimator. Thyroid 
scans are count based, with a minimum of 100.000 
counts advised. This means that the duration of the 
scan is determined by a preset number of counts and 
so the time of the scan varies from patient to patient 
(Kintzer and Peterson, 1994; Broome, 2006; Daniel 
and Brawner, 2006). The higher the uptake of pertech-
netate in the thyroid gland (i.e. the more increased 
the thyroid function), the sooner the preset amount 
of counts is reached, thus resulting in a shorter scan. 
On average, a diagnostic feline thyroid scan takes 
approximately 1 to 1.5 minutes. The use of different 
sedatives or anesthetics protocols has been described: 
ketamine, a combination of ketamine and diazepam, 
propofol, and the use of inhalant anesthetics. Cats may 
also be scanned awake (Beck et al., 1985; Mooney et 
al., 1992; Daniel et al., 2002; Henrikson et al., 2005; 
Volckaert et al., 2012; Peterson and Broome, 2015; 
Volckaert et al., 2016). The preferred drug or ideal 
protocol may vary however from patient to patient.
A pinhole collimator can be used in cats, even for 
quantitative measurements. It gives a more detailed 
image of the thyroid gland and can often distinguish 
two lobes when only one is seen on the two-dimen-
sional or planar scan, potentially missing a diagnosis 
of bilateral hyperthyroidism. An important disadvan-
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tage to the use of a pinhole collimator is the increased 
scan time due to a lower sensitivity, decreasing the 
tolerance to motion and requiring anesthesia (Mooney 
et al., 1992; Broome, 2006). 
Thyroid scintigram
Thyroid scintigraphy is the number one imaging 
modality in the diagnosis of hyperthyroidism in cats. 
It is sporadically used in cases of suspected post-treat-
ment hypothyroidism or rarely, in case of congenital 
hypothyroidism. A normal thyroid scintigram in cats 
shows the two thyroid lobes as elongated, oval struc-
tures in the cervical region, smoothly delineated, sym-
metrical in size and position and with a homogeneous 
distribution of the radionuclide (Figure 2). A certain 
level of thyroid lobe asymmetry can be present in 
euthyroid cats (Scrivani et al., 2007). Ectopic thyroid 
tissue is less commonly seen. It has been reported to be 
present in about 3.9% of hyperthyroid cats and is typi-
cally found on the midline and intrathoracic, usually 
in the cranial mediastinum (Beck et al., 1985; Kintzer 
and Peterson, 1994; Daniel and Brawner, 2006; Har-
vey et al., 2009; Daniel and Neelis, 2014; Peterson and 
Broome, 2015). 
In case of hyperthyroidism, several uptake patterns 
can be observed. The remaining normal thyroidal tis-
sue will be suppressed to a degree, depending on the 
serum T4 concentration and subsequent TSH suppres-
sion. In truly unilateral disease, the normal thyroid 
lobe should be entirely suppressed and is not visible on 
the scintigram. In hyperthyroid cats that are not under 
any form of treatment for hyperthyroidism, a normal 
looking thyroid lobe, aside a hyperactive lobe with 
marked increased radionuclide uptake is considered to 
be abnormal and indicates this lobe is also function-
ing autonomously. Multifocal nodular hyperplasia or 
adenomatous hyperplasia may have different features 
on the scintigram: an increased radionuclide uptake, 
homogeneous uptake, smooth margins, and usually 
bilateral in about 70% of the cases. With the help of a 
pinhole collimator, an enlarged, more detailed image 
of the thyroid gland can be obtained and the (multi)
focal appearance may be observed. In case of cystic 
adenomas, the area of the cyst may be seen as a pho-
topenic region, i.e. no accumulation of pertechnetate. 
When hyperactive nodules form a linear alignment 
rather than affecting the entire thyroid lobe, a “string 
of pearls” pattern can be seen.
Carcinomas are described as large areas of multi-
focal increased uptake, with a heterogeneous uptake 
pattern, irregular margins, and extending beyond the 
normal contours of the thyroid lobes (Figure 3). A 
linear multifocal pattern may indicate metastatic ex-
tension along the fascial planes, or uptake in ecto-
pic tissue. The thorax can be included in the scanned 
area to search for pulmonary metastases (Kintzer and 
Peterson, 1994; Hofmeister et al., 2001; Daniel and 
Brawner, 2006; Daniel and Neelis, 2014; Peterson and 
Broome, 2015).
In a study with 2096 hyperthyroid cats, the scinti-
graphic patterns of uptake were categorized and their 
percentage of occurrence was recorded as follows: 
31.7% had unilateral disease, 50.6% had bilateral-
asymmetric disease (two thyroid lobes of unequal 
size), 12.3% had bilateral-symmetric disease and 3.9% 
Figure 3. Thyroid scans of two cats with hyperthyroidism. A. typical image of a unilaterally affected hyperthyroid cat. 
The scan shows no features suggestive of malignancy. B. Image of excessive uptake of radionuclide over an area that 
is far more extensive than the normal contours of thyroid lobes. The uptake pattern is multifocal and heterogeneous. 
This patient also showed severe clinical signs of hyperthyroidism and thoracic X-rays demonstrated the presence of 
multiple pulmonary nodules, compatible with metastatic disease (L: left). 
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had multifocal disease, defined as three or more areas 
of increased uptake. Finally, 1.6% of the cats had a 
pattern not fitting into one of the categories. The most 
common location for foci of increased uptake was the 
cervical area (98.1%) followed by the thoracic inlet 
(13.5%) and the thoracic cavity (5.5%). A pattern con-
sistent with thyroid carcinoma was seen in 1.7% of the 
hyperthyroid patients (Peterson and Broome, 2015). It 
is important to note that carcinomas may show benign 
scintigraphic characteristics and vice versa. A reliable 
differentiation between benign and malignant thyroid 
tissue can therefore not be made based on the scinti-
gram (Daniel and Brawner, 2006; Harvey et al., 2009; 
Hibbert et al., 2009). 
 
Quantitative thyroid scintigraphy
The uptake of radionuclide in the thyroid gland is 
proportional to its metabolic activity. Therefore, quan-
tification of this uptake has been found to be a good 
assessor of thyroid activity. However, when evaluating 
quantitative parameters, it has to be borne in mind that 
several substances can interfere with the uptake by the 
thyroid sodium iodide symporters (NIS) and therefore 
with the uptake of pertechnetate or iodine.
Examples are competitive anion inhibitors (per-
chlorate, thiocyanate), sedatives and anesthetic medi-
cation, certain plants, thyroid hormone supplementa-
tion, the amount of dietary iodine, the administration 
of medicine, such as sulfonamide, phenylbutazone 
and anti-thyroid drugs (methimazole, carbimazole) 
or iodinated contrast media, e.g. iohexol (Nieckarz 
and Daniel, 2001; Fischetti et al., 2005; Daniel and 
Brawner, 2006; Capen, 2007; Shiel and Mooney, 
2007; Lee et al., 2010; Klein, 2012).
The radionuclide uptake can be easily and reliably 
assessed visually, but to assess the uptake in a more 
objective quantitative manner, semi-quantitative ratios 
have been introduced. Commonly used is the thyroid 
to salivary gland ratio (T/S), a reproducible and reli-
able parameter (Page et al., 2006). Regions of interest 
(ROIs) will be drawn around the thyroid lobes and 
the ipsilateral salivary glands. The ratio of the mean 
counts of these ROIs is then calculated. The normal 
T/S ratio in cats varies in the literature, with a range 
from 0.48 up to 1.9 (Beck et al., 1985; Kintzer and 
Peterson, 1994; Lambrechts et al., 1997; Nieckarz and 
Daniel, 2001; Daniel et al., 2002; Henrikson et al., 
2005; Daniel and Brawner, 2006; Page et al., 2006; 
Lee et al., 2010; Daniel and Neelis, 2014; Peterson 
and Broome, 2015). The T/S ratio increases up to 
twenty minutes after injection (Daniel et al., 2002). It 
has further been demonstrated that the T/S ratio will 
not significantly change within a time range of twenty 
minutes to two hours after the injection of pertechne-
tate. This is therefore a reliable time range to perform 
the thyroid scans (Nieckarz and Daniel, 2001; Fisch-
etti et al., 2005; Daniel and Brawner, 2006). The T/S 
ratio of the most active thyroid lobe or an average ratio 
of both lobes has been reported to be a simple method 
and good representation of the metabolic thyroidal 
status, correlating with serum T4 concentration both in 
normal and hyperthyroid cats at twenty minutes after 
tracer injection (Chun et al., 2002; Daniel et al., 2002; 
Fischetti et al., 2005; Peterson and Broome, 2015). 
Cats with only mildly elevated T4 concentrations may 
show T/S ratios overlapping with the normal range and 
with a large range of normal values reported, a cut-off 
T/S ratio of 2 has been suggested as being both sensi-
tive and specific for feline hyperthyroidism (Fischetti 
et al., 2005; Page et al., 2006). In a more recent study 
with 2096 cats, a lower cut-off ratio of 1.5 was pro-
posed (Peterson and Broome, 2015).
Another ratio that has been introduced is the thy-
roid to background ratio (T/B). This ratio is indepen-
dent of potential salivary gland disease and variation 
in uptake. The T/B ratio is calculated in a similar way 
to the T/S ratio, using the average counts of two ROIs, 
one around the thyroid and the second one at the level 
of the shoulder or axillary region, with a size similar to 
the thyroid ROI or using a fixed size ROI. The normal 
T/B ratio has a larger range, from 1.6 to 6.4 (Beck 
et al., 1985; Daniel and Brawner, 2006; Daniel and 
Neelis, 2014; Peterson and Broome, 2015). A correla-
tion with serum T4 has also been observed for the T/B 
ratio and a cut-off ratio of 6.1 has been proposed to be 
very sensitive to diagnose hyperthyroidism. However, 
the sensitivity of the T/S ratio has been found to be still 
slightly higher (Peterson and Broome, 2015). Persis-
tent post-therapy hyperthyroidism has been correlated 
to the T/B ratio, and cut-off ratios of  ≥ 5.8 (> 148 
MBq) and  ≥ 11 (259 MBq) have been suggested by 
the authors to increase the dose of radioiodine (Wal-
lack et al., 2010).
Whether the thyroid gland image and the T/S and 
T/B ratio change with age is not certain. In a study by 
Beck et al., these features were found to be similar 
between two age groups. However, the age range of 
the young adult group was not mentioned in the study, 
the ages of the group of older cats ranged from nine 
to eleven years. Another limitation of that study was 
the low number of patients included (n=10) (Beck et 
al., 1985). 
Finally, the percentage of the injected radionuclide 
that is accumulated by the thyroid gland can be mea-
sured. When using a form of radioactive iodine for 
this purpose, this is called a radioactive iodine uptake 
(RAIU) study. This study can be performed using 123I 
or 131I. The uptake of 131I in normal cats has shown 
to be variable in time, with 33% of the injected activ-
ity in the thyroid gland at 1 hour after injection, 21% 
between 4 and 24 hours after injection and 18% re-
maining at 48 hours after injection (Lambrechts et al., 
1997). In the past, these tracer studies were used for 
dose determination for therapeutic purposes (Broome 
et al., 1988). The percentage of radionuclide uptake by 
the thyroid gland can also be calculated using the safer 
technetium pertechnetate, as % technetium uptake or 
% thyroid uptake (%TcU). In the literature, the normal 
%TcU value ranges from 0.25 to 3.9% (Mooney et al., 
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1992; Nap et al., 1994; Daniel et al., 2002; Daniel and 
Brawner, 2006; Lee et al., 2010). In hyperthyroid cats, 
a correlation between the serum T4 and T3 with the 
%TcU at twenty minutes after injection of technetium 
has been demonstrated (Mooney et al., 1992; Fischetti 
et al., 2005). The mean %TcU at twenty minutes after 
injection has been determined in hyperthyroid cats as 
7% with a large range of 0.7 up to 61% (Mooney et 
al., 1992; Daniel et al., 2002; Fischetti et al., 2005). 
In contrast to the T/S ratio, the %TcU still increases 
in normal and hyperthyroid cats up to four hours af-
ter injection, and a significant difference has been 
reported in hyperthyroid cats between quantification 
at twenty and sixty minutes after injection (Nieckarz 
and Daniel, 2001; Fischetti et al., 2005). This has been 
contrasted in an earlier study, in which the maximum 
uptake was seen at one hour after injection, and there-
fore considered the ideal imaging time, followed by a 
decrease in %TcU, in both normal and hyperthyroid 
cats (Nap et al., 1994). However, different measure-
ment techniques were used in the evaluation of the 
percentage of technetium uptake, which could explain 
the different findings.
In the literature, the potential role of the 
thyroid:thyroid (T:T) ratio in the diagnosis of hyper-
thyroidism has been reported only once (Scrivani et 
al., 2007). The T:T ratio refers to a lobe-to-lobe ratio, 
where the value of the most active thyroid lobe is di-
vided by the value of the less active lobe. The T:T ratio 
in normal, euthyroid cats have been found to range 
from 1 to 2.1 (median 1.2), whereas in hyperthyroid 
cats, the T:T ratio ranges from 1.1 up to 12.6 (median 
2.5). A cut-off value of 1.5 has been suggested to be 
a good differentiator between normal and hyperthy-
roid cats, but the interpretation has to be made with 
care, since the T:T ratio has shown that asymmetry, 
although less commonly, may occur in normal cats as 
well (Scrivani et al., 2007). The use of these (semi-) 
quantitative parameters lies in a more complete evalu-
ation of the disease status of the patient and more 
patient-based dosimetric calculations for treatment 
with radioiodine as opposed to a fixed dose strategy.
Diagnostic pertechnetate scans have also been 
used to estimate thyroid lobe volume in hyperthyroid 
cats, and different formulas have been proposed to ap-
proach the true volume. In the literature, total thyroid 
volume estimated on scintigraphy in hyperthyroid cats 
ranges from a mean minimum total thyroid volume of 
1089 mm3 (standard deviation: 575) to a maximum 
of 28400 mm3, whereas thyroid single lobe volume 
has been described to range from 113 to 29157 mm3, 
depending on the formula used (Forrest et al., 1996; 
Volckaert et al., 2012; Volckaert et al., 2016). 
Neither method is perfect to diagnose and evaluate 
hyperthyroidism. The serum T4 concentration, as well 
as the T/S or T/B ratio on scintigraphy can fall within 
the normal reference range in cats with hyperthyroid-
ism. However, the sensitivity of both semi-quantitative 
ratios measured on the scintigrams has been reported 
to be superior to basal serum T4 concentrations and al-
low an earlier detection of the disease (Peterson, 2014; 
Peterson and Broome, 2015). It is therefore important 
to combine tests when there is a strong clinical suspi-
cion of occult or mild hyperthyroidism.
RADIOIODINE (131I) THERAPY IN HYPER-
THYROID CATS
Four treatment options are available for cats with 
hyperthyroidism: the use of radioactive iodine, medi- 
cinal treatment, dietary adjustments and surgery 
(thyroidectomy). Medicinal treatment means daily 
pilling and potential adverse side effects on other 
organs systems. Dietary adjustments in the form of low 
iodine diets, have been proposed for the management of 
hyperthyroidism. A specifically commercially devel-
oped food for this purpose is Hill’s® Y/D Prescription 
Diet, Hill’s, USA. To this day, no long-term follow-up 
studies are available assessing these diets. A very strict 
diet is required, as other foods and treats might contain 
high iodine content, and similar to antithyroid medica-
tion, the underlying pathology is not cured. This may 
result in an increased risk for malignant transformation 
secondary to continuing and therefore prolonged dis-
ease duration (Peterson, 2013a; Peterson et al., 2015; 
Scott-Moncrieff, 2015; Scott-Moncrieff et al., 2015). 
Surgery is an invasive procedure, holds an anesthetic 
risk in patients that often suffer from concurrent car-
diac or renal disease and recurrence of disease oc-
curs when not all thyroid tissue has been removed, 
especially when irresectable ectopic tissue is present. 
Another potential complication is the inadvertent re-
moval of parathyroid tissue, with hypoparathyroidism 
as a consequence. Radioiodine treatment has evidently 
also some drawbacks, such as the need for appropriate 
equipment, infrastructure and licenses, and a hospital-
ization period that varies between institutions depend-
ing on national radioprotection regulation, ranging 
from five days to several weeks after treatment. More-
over, if successful, radioiodine therapy is a permanent 
treatment. This is an important factor as hyperthy-
roid cats can suffer from concomitant disease, i.e. 
commonly underlying chronic kidney disease, which 
might be easier to monitor and control with medicinal 
treatment. On the other hand, in cats of which the cur-
rent health status allows so, radioiodine therapy is a 
safe, easy and permanent solution in most cases and 
does not require anesthesia (Kintzer, 1994; van Hoek 
et al., 2007; Mooney, 2010; Peterson, 2014). Radio-
iodine therapy has also been reported to be associated 
with a significantly longer survival time than in case of 
the use of medicinal treatment only. Cats treated with 
radioiodine show an increased median survival time of 
two years compared to cats treated with methimazole. 
Cats that were treated with a combination of methima-
zole followed by radioiodine show an extra median 
survival time of 3.3 years compared to those treated 
with methimazole only (Milner et al., 2006). Today, 
if the patient’s condition allows so, radioiodine is the 
therapy of choice in the majority of cases. 
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Radioiodine therapy
The radionuclide used for therapy is 131I. It differs 
from 123I by emitting not only γ-rays (364 keV), but 
also the therapeutic β- particles. It has a physical half-
life of 8.06 days and is excreted mainly by the kidneys, 
saliva and feces. Radioactive iodine is treated by the 
body in the same way as non-radioactive iodine, and 
will be trapped by the follicular cells of the thyroid 
gland and organified. The uptake of iodine may be 
influenced by the same factors that influence techne-
tium uptake, i.e. antithyroid drugs, alimentary iodine, 
contrast media and iodine-based surgical solutions 
(Kintzer and Peterson, 1994; Adams, 2006; Peremans 
et al., 2008). When the 131I decays, it will emit its 
high energy, mostly in the form of β- particles, for 
90% in a radius of ± 1 mm with a maximum travel 
distance of 2 mm and an average path length of 400 
µm. This will create destruction of tissues in the im-
mediate vicinity, sparing surrounding structures like 
the external parathyroid glands. Due to the low TSH 
concentration in hyperthyroidism, the functionality 
of normal thyroid tissue will be suppressed and this 
tissue will therefore not concentrate the radioactive 
iodine. The remaining 10% of the local radiation is 
γ-radiation, which can be used for imaging purposes 
(Gerber et al., 1994; Mooney, 1994, Kintzer and Pe-
terson, 1994; Adams, 2006; Peterson, 2014). As ex-
pected, a significantly increased uptake and higher 
turnover of radioiodine are seen in hyperthyroid cats 
versus euthyroid cats. The peak of uptake in normal 
cats is at 48 hours after injection (20.6%), whereas in 
hyperthyroid cats, the maximum uptake is faster and 
occurs around 24 hours (56%). In this population, the 
uptake may range up to 87.7% (Sjollema et al, 1989). 
In a study by Lambrechts et al.,(1997), a different up-
take pattern after oral administration of radioiodine in 
euthyroid cats was described, with a mean uptake of 
33% at one hour followed by a decline to 18% at 48 
hours. As with pertechnetate, the use of anti-thyroid 
medication, such as methimazole, may influence the 
uptake of radioiodine. It is generally advised to dis-
continue any possible anti-thyroid medication before 
therapy. The time of discontinuation however varies 
from institution to institution, and depends on whether 
the patient’s clinical condition allows a prolonged time 
off medication. A time range of 4 to 14 days has been 
reported in the literature (Slater et al., 1994; Théon et 
al., 1994; Peterson and Becker, 1995; Forrest et al., 
1996; Nykamp et al., 2005; Peterson and Broome, 
2015). A so called “rebound effect” has been reported, 
where an increased uptake of radioiodine is observed 
after stopping anti-thyroid medication. The uptake is 
most significantly increased four to nine days after 
the withdrawal (Nieckarz and Daniel, 2001; Shiel and 
Mooney, 2007). At the department of Small Animal 
Orthopedics and Medical Imaging of the Faculty of 
Veterinary Medicine (UGent), a withdrawal of 14 days 
is generally recommended to avoid any possible re-
bound effect. If the patient’s condition does not allow 
this, a withdrawal of three days is considered accept-
able, again allowing enough time to avoid a possible 
rebound effect.
Regarding radioiodine dose estimation, different 
protocols may be found in the literature. A scoring 
system has been proposed, based on the severity of 
clinical signs, pretherapy serum T4, size and number 
of thyroid nodules, and the patient’s body weight. 
Radioiodine dose can also be estimated based on the 
total thyroid volume or weight, on the T/B ratio or on 
RAIU tracer studies. Another method is a fixed empiri-
cal dose system (Turrell et al., 1984; Broome et al., 
1988; Meric and Rubin, 1991; Mooney, 1994; Kintzer 
and Peterson, 1994; Slater et al., 1994; Théon et al., 
1994; Peterson and Becker, 1995; Forrest et al., 1996; 
Chun et al., 2002; Nykamp et al., 2005; Adams, 2006; 
Wallack et al., 2010). The empirical dose advised, is 
148 to 185 MBq for adenomas or adenomatous hyper-
plasia, administered by intravenous or subcutaneous 
injection. Both routes of administration have been 
found effective, without side effects and with the same 
final outcome (Meric and Rubin, 1990; Mooney, 1994; 
Théon et al., 1994; Peterson and Becker, 1995; Ad-
ams, 2006). The ideal method of dose estimation has 
not yet been determined, although most methods seem 
to be effective for a positive treatment outcome. Oral 
administration of radioiodine has also been reported, 
using slightly higher doses in the form of capsules. 
The major disadvantage is the high risk of spilling, 
increasing the exposure of personnel and potential 
contamination of the premises, as cats may not always 
be cooperative. Additionally, the hospitalization pe-
riod for these patients is longer (Malik et al., 1993).
Doses used for thyroid carcinomas are three to 
ten times higher than for benign disease, typically 
reported around 1110 to 1480 MBq and administered 
intravenously (Adams, 2006; Harvey et al., 2009; Hib-
bert et al., 2009). In case the patient remains hyperthy-
roid, the treatment can then be repeated. Radioiodine 
is well tolerated, even in higher doses. The only im-
portant complication reported in cats is the induction 
of iatrogenic hypothyroidism. In a study by Turrell 
et al., (1984), a transient voice change was reported 
in a cat and Peterson and Becker (1995) reported a 
transient period of difficulty in swallowing, presum-
ably induced by radiation thyroiditis. After radioiodine 
therapy, control scans can be performed to confirm 
sufficient uptake. When a thyroid carcinoma is sus-
pected or confirmed, follow-up scans are advised at 
four to six weeks after therapy and to be repeated at a 
three to six months’ interval to ensure tumor regres-
sion or detect potential tumor recurrence. 
The effect of radioiodine on the serum T4 con-
centration occurs rapidly. The most rapid decrease is 
seen the first three to six days after treatment. Fifty-
five percent of patients were shown to have normal 
serum T4 4 days after treatment, 74% was reached 
after eight days and 83% had normal serum T4 by one 
month (Meric et al., 1986). Follow-up of the serum 
T4 concentration may first show a marked decreased 
value, below reference range, without any clinical con-
sequence. This transient, post-therapy hypothyroidism 
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is presumed to be the time when normal tissue, previ-
ously suppressed, starts to regenerate and slowly starts 
functioning normally again. With a small delay, the 
T4 concentration then restores itself to normal values 
in most cases. Regular monitoring is therefore use-
ful, and more importantly, a final control blood test 
should not be performed too early after treatment. 
Waiting six months is often advised. However, the 
ideal time for a recheck after treatment is unknown 
and may vary from patient to patient (Meric and Ru-
bin, 1990; Mooney, 1994; Théon et al., 1994; Peter-
son and Becker, 1995). Given the negative effect of 
a decreased thyroid function on the renal function, 
it may be indicated to start thyroid supplementation 
before six months after therapy (Brooke et al., 2012; 
Dragović, 2012; Vikrant et al., 2013). In these cases, 
it is also important to exclude possible non-thyroidal 
illness and make a good but often difficult diagnosis 
of true hypothyroidism (Mooney et al., 1996; Shiel 
and Mooney, 2007; Mooney, 2010; Peterson, 2013b).
Radioiodine therapy outcome
In the literature, radioiodine therapy is generally 
considered a very effective treatment with a success 
rate ranging from 70 to 95% (Meric et al., 1986; Meric 
and Rubin, 1990; Malik et al., 1993; Kintzer and Pe-
terson, 1994; Mooney, 1994; Slater et al., 1994; Théon 
et al., 1994; Peterson and Becker, 1995; Forrest et 
al., 1996; Nykamp et al., 2005; Wallack et al., 2010). 
The definition of a successful therapy is however not 
always clearly defined and could refer to the resolu-
tion of clinical signs, as well as a serum T4 within 
the normal reference range, or the combination of 
both. Some studies therefore include cats that are (sub)
clinically hypothyroid in their successful group. The 
median time of follow-up also ranges strongly from 
1 to 18 months (Meric et al., 1986; Meric and Rubin, 
1990; Slater et al., 1994; Théon et al., 1994; Peterson 
and Becker, 1995; Forrest et al., 1996; Nykamp et al., 
2005; Wallack et al., 2010).
Several factors influencing and/or predicting ra-
dioiodine therapy outcome have been suggested. In a 
study by Peremans et al. (2008), iohexol, a commonly 
used iodinated contrast medium in radiography and 
CT, was surprisingly not found to have any significant 
impact on the outcome when given 24 hours prior 
to treatment, despite clear decreased thyroid absorp-
tion of the radioiodine. However, the dose of iodine 
(iohexol) administered in this study for glomerular 
filtration rate (GFR) measurements in hyperthyroid 
cats, was lower than the dose normally used for most 
contrast studies. Moreover, only a relatively small 
group of cats was included precluding definite conclu-
sions (Peremans et al., 2008). The pre-therapy serum 
T4 concentration was observed to correlate to post-
therapy T4 measurements, but not to a degree where 
it could predict therapy outcome (Chun et al., 2002; 
Wallack et al., 2010). In earlier studies, higher pre-
therapy serum T4 concentrations have been suggested 
to increase the risk of persistent hyperthyroidism (Pe-
terson and Becker, 1995; Forrest et al., 1996). Signifi-
cantly higher T/B ratios have been noted in cats that 
showed persistent hyperthyroidism after radioiodine 
therapy, suggesting this ratio could predict therapy 
failure or alarm clinicians to increase the administered 
dose of radioiodine (Wallack et al., 2010). The pre-
therapy T/S ratio, the severity of clinical signs or the 
timing at which methimazole treatment was stopped 
prior to the radioiodine therapy have not been found 
factors, which may help to predict therapy outcome 
(Chun et al., 2002; Wallack et al., 2010). In addition, 
no significant relationship with a persistent hyperthy-
roid outcome has been found for the presence of ecto-
pic tissue, bilateral versus unilateral disease or previ-
ous anti-thyroid medication (Forrest et al., 1996). On 
the contrary, Nykamp et al. (2005) observed a signifi-
cant effect of bilateral disease towards a hypothyroid 
outcome, with an almost double increased chance of 
post-therapy hypothyroidism in patients with bilateral 
disease. 
Thyroid volume estimated on diagnostic pertechne-
tate scans, has also been suggested as a factor influenc-
ing radioiodine therapy outcome. Larger total thyroid 
volumes have been reported to increase the risk of 
persistent hyperthyroidism after treatment. However, 
no cut-off values have been determined (Peterson and 
Becker, 1995; Forrest et al., 1996; Volckaert et al., 
2016). Forrest et al. (1996) also suggested that oral 
administration of radioiodine is less successful than 
the intravenous route. 
CONCLUSION
Thyroid scintigraphy is a commonly used and ex-
cellent modality in the diagnosis and management 
of feline hyperthyroidism and should ideally be per-
formed in all hyperthyroid patients, especially when 
definitive treatment like radioiodine or surgery is con-
sidered. Radioiodine treatment shows a good outcome 
in most patients and is not associated with any signifi-
cant side effects. It remains therefore the treatment of 
choice, if the patient’s condition allows it.  
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